Delaying a treatment switch in antiretroviral-treated HIV type 1-infected patients with detectable drug-resistant viremia does not have a profound effect on immune parameters: AIDS Clinical Trials Group Study A5115

Allan R. Tenorio, Hongyu Jiang, Yu Zheng, Barbara Bastow, Daniel R. Kuritzkes, John A. Bartlett, Steven G. Deeks, Alan L. Landay, Sharon A. Riddler

Research output: Contribution to journalArticlepeer-review

Abstract

Some patients are unable to achieve and maintain an undetectable plasma HIV-1 RNA level with combination antiretroviral therapy (ART) and are therefore maintained on a partially suppressive regimen. To determine the immune consequences of continuing ART despite persistent viremia, we randomized 47 ART-treated individuals with low to moderate plasma HIV-1 RNA levels (200-9999 copies/ml) to either an immediate switch in therapy or a delayed switch (when plasma HIV-1 RNA became ≥10,000 copies/ml). After 48 weeks of follow-up, naive and memory CD4+ T cell percents were comparable in the two groups. The proportion of subjects with a lymphocyte proliferative response to Candida, Mycobacterium avium- intracellulare complex, or HIV-gag was also not significantly different at week 48. Delaying a treatment switch in patients with partial virologic suppression and stable CD4+ T cells does not have profound effects on immune parameters.

Original languageEnglish (US)
Pages (from-to)135-139
Number of pages5
JournalAIDS Research and Human Retroviruses
Volume25
Issue number2
DOIs
StatePublished - Feb 1 2009
Externally publishedYes

ASJC Scopus subject areas

  • Immunology
  • Virology
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Delaying a treatment switch in antiretroviral-treated HIV type 1-infected patients with detectable drug-resistant viremia does not have a profound effect on immune parameters: AIDS Clinical Trials Group Study A5115'. Together they form a unique fingerprint.

Cite this